FIELD: medicine; pharmaceutics.
SUBSTANCE: present document discloses pharmaceutical compositions containing methylnaltrexone, lauryl sulphate or docusate and at least one component of an oil, a surfactant or a cosolvent, wherein methylnaltrexone and lauryl sulphate or docusate are present as an ion pair.
EFFECT: pharmaceutical compositions can additionally contain a surfactant for providing self-emulsifying methylnaltrexone delivery systems.
31 cl, 6 dwg, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF METHYL NALTREXONE FOR TREATING IRRITABLE COLON SYNDROME | 2004 |
|
RU2373936C2 |
| AQUEOUS SUSPENSIONS OF RILUZOL | 2010 |
|
RU2498802C2 |
| ABIRATERONE ACETATE FORMULATION | 2014 |
|
RU2732136C2 |
| APIXABAN LIQUID FORMULATIONS | 2013 |
|
RU2660358C2 |
| ORAL CELECOXIB COMPOSITION FOR PAIN TREATMENT | 2017 |
|
RU2745196C2 |
| PERORAL COMPOSITIONS CONTAINING ESTER 17- HYDROXYPROHESTERON, AND CORRESPONDING METHODS | 2012 |
|
RU2640912C2 |
| LIPID COMPOSITIONS OF RACECADOTRIL | 2013 |
|
RU2632441C2 |
| FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USING THEM | 2007 |
|
RU2539387C2 |
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2589842C2 |
| RACECADOTRIL LIPID COMPOSITIONS | 2014 |
|
RU2662069C2 |
